ohio state university medical center

(Ohio State University Medical Center) To better understand how cells become cancerous, a new study by Ohio State University cancer researchers looks at four genes that help regulate cell growth in embryos and contribute to cancer in adults.

The genes are generally believed to work together to help control cell proliferation. But this study, published in the journal Nature, shows that mice need just one of the four genes to develop from fertilized eggs through adulthood.

(Ohio State University Medical Center) Data from 260 hospitals across the United States has led to the creation of a new method for physicians to more accurately determine the severity of heart failure in patients upon hospital admission, with a goal of reducing in-hospital mortality and more quickly identifying triage methods and treatment decisions.

The model is discussed in the July 29 issue of the Journal of the American College of Cardiology. The lead author is Dr.

William Abraham, director of cardiovascular medicine at Ohio State University Medical Center.

(Ohio State University Medical Center) Researchers at the Ohio State University Medical Center have designed equipment to provide high resolution images of the heart at a critical stage of testing that have previously been difficult to obtain using standard testing procedures.

Superior images of the heart are obtained with a test lasting less than one hour.

(Ohio State University) The air people breathe while walking in the park, working in the garden or shopping downtown may be unhealthy enough to seriously spike their blood pressure, a new study suggests.

Cardiovascular researchers at The Ohio State University Medical Center are the first to report a direct link between air pollution and its impact on high blood pressure, or hypertension.

If the results from these animal studies hold up, this could be important for human health.

(Ohio State University Medical Center) A team of researchers from Ohio State University's Comprehensive Cancer Center and the University's College of Veterinary Medicine have received a $10.9 million, five-year grant from the National Cancer Institute to further their studies of retrovirus-associated cancer.

(Ohio State University Medical Center) A novel electronic device designed to "zap" away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at the Ohio State University Medical Center.

(Ohio State University Medical Center) A new study led by Ohio State University cancer researchers shows that people with acute myeloid leukemia whose leukemic cells have mutations in the RAS gene are more likely to be cured when treated after remission with high doses of the drug cytarabine.

It also suggests that testing for RAS mutations might help doctors identify which AML patients should receive high-dose cytarabine as their post-remission therapy.

The findings could change how doctors manage these patients.

(Ohio State University Medical Center) Viruses genetically designed to kill cancer cells offer a promising strategy for treating incurable brain tumors, but the body often eliminates the viruses before they can eliminate the tumor.

This animal study helps explain why this happens. The research shows that as the viruses destroy tumor cells, the cells release proteins that stimulate new blood-vessel growth to the tumor.

These vessels bring immune cells that eradicate the viruses and actually stimulate regrowth of the tumor.

(Thomas Jefferson University) Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia and Ohio State University Medical Center in Columbus have identified a common signature of tiny, specific pieces of non-coding genetic material known as microRNAs (miRNAs) that may be directly involved in the spread of cancer.

The findings, reported at the annual meeting of the American Society of Clinical Oncology in Chicago, may represent a novel diagnostic tool in characterizing gene targets in metastatic cancer.

(Ohio State University Medical Center) An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows.

The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process.

The study showed that the agent kept mice with a precancerous condition from developing advanced prostate cancer.